Dyne Therapeutics (NASDAQ:DYN) Posts Quarterly Earnings Results, Misses Estimates By $0.25 EPS

Dyne Therapeutics (NASDAQ:DYN) announced its quarterly earnings data on Tuesday. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25), Zacks reports.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $30.31 on Friday. Dyne Therapeutics has a 1-year low of $9.76 and a 1-year high of $47.45. The firm’s fifty day simple moving average is $32.58 and its 200-day simple moving average is $35.08.

Insider Buying and Selling

In other news, SVP Richard William Scalzo sold 1,390 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the sale, the senior vice president now directly owns 98,568 shares of the company’s stock, valued at approximately $3,405,524.40. This trade represents a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Dirk Kersten sold 23,671 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total value of $836,769.85. Following the transaction, the director now directly owns 99,652 shares of the company’s stock, valued at $3,522,698.20. This represents a 19.19 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 158,975 shares of company stock worth $5,693,789. Corporate insiders own 20.77% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Guggenheim upped their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Morgan Stanley raised their target price on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus upped their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.